• Neuromedin S (rat): Practical Assay Workflow

  2026-09-27

  Neuromedin S (rat) provides a defined peptide input for controlled studies of neuromedin U receptor signaling and related GPCR/G protein responses. Use it in research assays after establishing model-specific concentrations and controls; it is not intended for diagnostic or medical use.

• 3-Bromopyruvate Reverses Cetuximab Resistance in CRC

  2026-09-26

  This study reports that 3-bromopyruvate combined with cetuximab suppresses colorectal cancer cells with intrinsic or acquired cetuximab resistance, with evidence implicating FOXO3a-linked autophagy, ferroptosis, and apoptosis. The work offers a mechanistic rationale for testing the combination, while leaving clinical benefit and the relative contribution of each cell-death pathway to be established.

• Nicotine Signaling and CKD Progression in Smokers

  2026-09-25

  Jain and Jaimes review clinical and experimental evidence that nicotine may contribute to chronic kidney disease progression through renal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and profibrotic signaling. Their synthesis helps researchers distinguish nicotine-specific mechanisms from the broader effects of cigarette smoke and identify useful questions for kidney injury models, while emphasizing that the evidence does not establish nicotine as the sole cause of smoking-related renal damage.

• Halazone Beyond Disinfection: A Translational Research Lens

  2026-09-25

  Halazone links oxidative water disinfection with a distinct neurophysiological effect: disruption of sodium-current inactivation. This article examines the evidence, practical experimental considerations, and limits researchers should weigh when translating these findings across disciplines.

• Rucaparib Workflows for DNA Repair and HCC

  2026-09-24

  Use Rucaparib to test how PARP inhibition interacts with DNA damage, radiation, and repair-deficient states—with assay controls that separate target response from general toxicity. A 2024 HCC study links spliceosome regulation to PARP-inhibitor sensitivity, offering a rationale for testing SmD2 and BRCA1/FANC splicing alongside, but not as a substitute for, direct Rucaparib validation.

• Ac-YVAD-CMK for Caspase-1 Assay Design

  2026-09-24

  Use Ac-YVAD-CMK to test whether caspase-1 activity contributes to cytokine maturation and pyroptosis—without confusing this intervention with membrane repair itself. This workflow connects the compound to Kupffer-cell infection research while separating published findings from practical assay recommendations.

• PORCN Inhibition for Sclerosteosis: Study Findings

  2026-09-23

  A 2025 study found that inhibiting the Wnt-processing enzyme PORCN with LGK974 reduced osteoblast activity in vitro and limited selected high-bone-mass features in Sost-deficient mice. The findings support further investigation of Wnt pathway modulation for sclerosteosis, while the animal data and sex-dependent biomarker response leave important questions for translation.

• Alcian Blue & Nuclear Fast Red Staining Kit Guide

  2026-09-23

  Build a clear, reproducible workflow for acid mucin visualization, cartilage-matrix assessment, and chondrogenic differentiation staining. This guide combines practical assay parameters with lessons from small-biopsy pathology research, while separating validated product facts from conditions that require laboratory optimization.

• Oridonin Suppresses Inflammation in Esophageal Cancer

  2026-09-22

  A 2025 mouse study links oridonin treatment with reduced esophageal inflammation and tumor-associated signaling through the TLR4/NF-κB/NLRP3 inflammasome axis. Its integrated histological, biochemical, transcriptional, protein, and blood-cell analyses provide a useful mechanistic framework, while the model design still limits direct translation to patients.

• Brassinolide Research Workflows

  2026-09-22

  Brassinolide connects plant developmental assays with translational models of PC-3 apoptosis and diabetic glucose regulation. This practical guide covers solution handling, light-controlled root experiments, apoptosis readouts, animal-study design, and troubleshooting for reproducible results.

• Octanoic Acid, PPARγ, and Macrophages in IBD

  2026-09-21

  The reference study identifies octanoic acid-rich enteral nutrition as a regulator of intestinal macrophage polarization through the PPARγ/STAT-1/STAT-6 axis. Its combination of animal-group comparisons, pathway perturbation, and RAW264.7-cell experiments provides a mechanistic framework for evaluating nutritional control of inflammatory bowel disease rather than treating enteral nutrition as a nonspecific intervention.

• Epinephrine in Local Anesthesia: Evidence and Dose

  2026-09-21

  This 1986 review synthesizes how vasoconstrictors alter local-anesthetic performance, with particular attention to epinephrine’s alpha- and beta-adrenergic effects and systemic risks. Its practical conclusion is that 1:200,000 epinephrine may provide effective anesthetic depth and duration in many dental settings while limiting unnecessary exposure.

• TAK-715: p38 MAPK Inhibitor Workflow

  2026-09-20

  TAK-715 is a selective p38α-focused tool for connecting kinase activity with cytokine output in cell and inflammation models. This workflow combines practical dosing, phospho-signaling readouts, and a conformation-aware assay strategy to distinguish direct pathway inhibition from downstream biological effects.

• CHIR 99021 Trihydrochloride in Organoid Assays

  2026-09-19

  CHIR 99021 trihydrochloride is a selective GSK-3 inhibitor for connecting stem-cell state, organoid diversity, and metabolic phenotypes. This article presents a decision framework for using GSK-3 inhibition as a tunable assay variable rather than treating it as a universal organoid recipe.

• AZD3463: A Systems Strategy for ALK-Driven Research

  2026-09-18

  AZD3463 offers translational researchers a dual ALK/IGF1R inhibitor framework for interrogating oncogenic signaling, apoptosis, autophagy, and chemotherapy response in neuroblastoma models. This thought-leadership analysis connects pathway biology with experimental design, evidence boundaries, and strategic opportunities for ALK-driven cancer research.

1127 records 6/76 page Previous Next First page 上5页 678910 下5页 Last page